Diarrhoea · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Diarrhoea ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse events: Neutrophils decreased ‐ · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Neutrophils decreased ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse effect: fatigue · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Fatigue ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Cognitive function · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Incidence of dementia · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding (intracranial and extracranial) · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Functional ability · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Stroke or transient ischaemic attack · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Any adverse events (excluding major bleeding) · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Withdrawal from study medication · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
Seizure freedom · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants seizure‐free at 24 months after randomization ‐ not reported · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low
Proportion of participants seizure‐free at 12 months after randomization · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion free from seizures (Engel Class 1) at 2 years · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found